The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma

Phase II trial of hu14.18-IL2 (EMD 273063) for patients with metastatic melanoma

(2017) M. R. Albertini et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children’s Oncology Group (COG) phase II study

(2017) S. Shusterman et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/- Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN- 2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696

(2009) J. M. Kirkwood et al.   CLINICAL CANCER RESEARCH

Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma

(2009) Luis H. Camacho et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Intratumoral immunocytokine treatment results in enhanced antitumor effects

(2008) Erik E. Johnson et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group

(2008) Andrew L. Gilman et al.   JOURNAL OF CLINICAL ONCOLOGY